Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds [Microdose]
Wednesday, February 26, 2025 1 min read
Key Takeaway: Enveric Biosciences has obtained its first U.S. patent for the EVM401 Series, a new class of compounds aimed at treating neuropsychiatric disorders. These psychedelic-inspired therapies promise to deliver the advantages of traditional psychedelics while avoiding their hallucinogenic side effects, potentially revolutionizing mental health treatment approaches.
Price reaction · baseline $14.16 (2025-02-25 close) · hit pre-market · 1 other ENVB headline(s) in the window, move may be shared
day 0 close
+94.9%
day 1
+79.7%
day 3
+120.3%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences secures its first U.S. patent.
The EVM401 Series could transform mental health treatments.
Offers benefits of psychedelics without hallucinogenic effects.
Full Press Release Details
In a significant development for mental health treatments, Enveric Biosciences (NASDAQ: ENVB) has secured its first U.S. patent for a novel series of compounds that could transform how we approach neuropsychiatric disorders. The company’s EVM401 Series represents a growing class of psychedelic-inspired therapies designed to provide the benefits of traditional psychedelics without the hallucinogenic effects that can limit their clinical use.
Full Article >>
Frequently Asked Questions
What is the EVM401 Series?
The EVM401 Series is a novel class of compounds developed by Enveric Biosciences for treating neuropsychiatric disorders.
What are the benefits of the EVM401 Series?
These compounds aim to provide the therapeutic effects of traditional psychedelics without the hallucinogenic side effects.
When did Enveric secure the patent?
Enveric Biosciences has recently secured its first U.S. patent for the EVM401 Series.
How could this patent impact mental health treatments?
The patent could transform mental health treatments by offering new, effective therapies for neuropsychiatric disorders.